Suppr超能文献

在中国人群中,原发性肿瘤免疫评分无法预测肝切除术后结直肠癌肝转移的预后。

Primary tumor immune score fails to predict the prognosis of colorectal cancer liver metastases after hepatectomy in Chinese populations.

作者信息

Lin Hao-Cheng, Shao Qiong, Liang Jie-Ying, Wang Yun, Zhang Hui-Zhong, Yuan Yun-Fei, Li Bin-Kui, Wu Xiao-Jun, Chen Gong, Ding Pei-Rong, Lu Zhen-Hai, Pan Zhi-Zhong, Wang De-Shen, Qiu Miao-Zhen, Wang Zhi-Qiang, Wang Feng-Hua, Xu Rui-Hua, Li Yu-Hong

机构信息

State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.

出版信息

Ann Transl Med. 2021 Feb;9(4):310. doi: 10.21037/atm-20-4932.

Abstract

BACKGROUND

Increasing evidence suggests that the immune score is significantly associated with cancer prognosis. However, the prognostic role of primary tumor immune score in colorectal cancer liver metastases (CRLM) after hepatectomy in Chinese patients has not been reported. The present study is designed to investigate whether the immune score of primary tumor can predict the postoperative survival of liver metastases in Chinese patients.

METHODS

A total of 131 patients diagnosed with CRLM were included, and the corresponding primary tumor and liver metastasis specimens were acquired. An immune score ranging from 0 to 4 was established based on the counts and densities of CD3 and CD8 T cells in the core tumor (CT) and the invasive margin (IM). Relapse-free survival (RFS) and overall survival (OS) were analyzed by Kaplan-Meier curves to assess the prognostic role of primary tumor immune score. Furthermore, we conducted a comprehensive search of the Gene Expression Omnibus (GEO) and selected stage IV colorectal cancer (CRC) patients with liver metastasis to compare the tumor-infiltrating T cell profiles of the primary tumor and liver metastases by CIBERSORT.

RESULTS

Patients with high immune scores in the primary tumor has no significantly better RFS and OS after hepatectomy than those with low immune scores [median RFS (95% CI): 19.13 (10.07-28.20) . 27.13 (15.97-38.29) months, P=0.604; median OS (95% CI): 64.37 (35.96-92.78) . 40.07 (32.54-47.59) months, P=0.652]. Data collected from the GEO indicates that the proportion of CD8 T cells and total T cells in the primary tumor and liver metastatic lesion are also not significantly correlated (CD8 T cells: r =0.030, P=0.468; total T cells: r =0.165, P=0.076).

CONCLUSIONS

The immune score of the primary tumor fails to predict the prognosis of CRLM after hepatectomy in Chinese patients.

摘要

背景

越来越多的证据表明免疫评分与癌症预后显著相关。然而,中国患者肝切除术后原发性肿瘤免疫评分在结直肠癌肝转移(CRLM)中的预后作用尚未见报道。本研究旨在探讨原发性肿瘤的免疫评分能否预测中国患者肝转移的术后生存情况。

方法

共纳入131例诊断为CRLM的患者,并获取相应的原发性肿瘤和肝转移标本。根据核心肿瘤(CT)和浸润边缘(IM)中CD3和CD8 T细胞的计数和密度建立了范围为0至4的免疫评分。采用Kaplan-Meier曲线分析无复发生存期(RFS)和总生存期(OS),以评估原发性肿瘤免疫评分的预后作用。此外,我们对基因表达综合数据库(GEO)进行了全面检索,并选择了伴有肝转移的IV期结直肠癌(CRC)患者,通过CIBERSORT比较原发性肿瘤和肝转移灶中肿瘤浸润性T细胞谱。

结果

原发性肿瘤免疫评分高的患者肝切除术后的RFS和OS并不显著优于免疫评分低的患者[中位RFS(95%CI):19.13(10.07 - 28.20). 27.13(15.97 - 38.29)个月,P = 0.604;中位OS(95%CI):64.37(35.96 - 92.78). 40.07(32.54 - 47.59)个月,P = 0.652]。从GEO收集的数据表明,原发性肿瘤和肝转移灶中CD8 T细胞及总T细胞的比例也无显著相关性(CD8 T细胞:r = 0.030,P = 0.468;总T细胞:r = 0.165,P = 0.076)。

结论

原发性肿瘤的免疫评分无法预测中国患者肝切除术后CRLM的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/233f/7944305/d365622fd376/atm-09-04-310-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验